Table 3.
Maternal report of use of medications containing acetaminophen during pregnancy in the IKIDS cohort for all participants with a child enrolled at birth and each subsample with CBCL data available at 26.5-28.5, 36-38, and 46-48 months.
| Participants with an infant enrolled in study (n = 535) |
Participants who completed the CBCL when their child was 26.5-28.5 months (n = 268) |
|||||||
|---|---|---|---|---|---|---|---|---|
| 1st Trimester N (%) |
2nd Trimester N (%) |
3rd Trimester N (%) |
Entire Pregnancy N (%) |
1st Trimester N (%) |
2nd Trimester N (%) |
3rd Trimester N (%) |
Entire Pregnancy N (%) |
|
| None | 220 (41.1) | 250 (46.7) | 340 (63.6) | 155 (29.0) | 125 (46.6) | 139 (51.9) | 181 (67.5) | 87 (32.5) |
| Any | 312 (58.3) | 283 (52.9) | 194 (36.3) | 377 (70.5) | 143 (53.4) | 129 (48.1) | 87 (32.5) | 181 (67.5) |
| Missing | 3 (0.6) | 2 (0.4) | 1 (0.2) | 3 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Mean (SD) | 17.9 (39.7) | 22.0 (44.1) | 15.1 (25.6) | 39.1 (75.1) | 13.7 (26.3) | 20.6 (47.1) | 12.6 (21.9) | 31.6 (67.5) |
| Median (IQR) | 5.0 (14.0) | 7.5 (15.0) | 5.0 (12.0) | 14.0 (31.8) | 5.8 (14.0) | 7.0 (13.0) | 4.0 (10.8) | 12.0 (27.0) |
| Range | 0.5 - 314.0 | 0.5 - 350.0 | 0.5 - 153.0 | 1.0 - 641.0 | 1.0 - 248.5 | 0.5 - 339 | 0.5 - 119.5 | 1.0 - 550.5 |
| Formulation | ||||||||
| Paracetamol alone | 258 (82.7) | 229 (80.9) | 158 (81.4) | 287 (76.1) | 118 (82.5) | 104 (80.6) | 72 (82.8) | 138 (76.2) |
| Acetaminophen in combination | 25 (8.0) | 19 (6.7) | 17 (8.8) | 26 (6.9) | 14 (9.8) | 13 (10.1) | 8 (9.2) | 18 (9.9) |
| with other active ingredients | ||||||||
| Multiple formulations | 29 (9.3) | 35 (12.4) | 19 (9.8) | 64 (17.0) | 11 (7.7) | 12 (9.3) | 7 (8.0) | 25 (13.8) |
| Indication | ||||||||
| Pain | 214 (68.6) | 202 (71.4) | 134 (69.1) | 235 (62.3) | 106 (74.1) | 96 (74.4) | 64 (73.6) | 114 (63.0) |
| Other | 39 (12.5) | 31 (11.0) | 26 (13.4) | 54 (14.3) | 23 (16.1) | 19 (14.7) | 13 (14.9) | 35 (19.3) |
| Multiple reasons given | 27 (8.7) | 28 (9.9) | 19 (9.8) | 61 (16.2) | 14 (9.8) | 11 (8.5) | 9 (10.3) | 31 (17.1) |
| Missing | 32 (10.3) | 22 (7.8) | 15 (7.7) | 27 (7.2) | 0 (0.0) | 3 (2.3) | 1 (1.1) | 1 (0.6) |
| Participants who completed the CBCL when their child was 36-38 months (n = 240) |
Participants who completed the CBCL when their child was 46-48 months (n = 180) |
|||||||
| 1st Trimester N (%) |
2nd Trimester N (%) |
3rd Trimester N (%) |
Entire Pregnancy N (%) |
1st Trimester N (%) |
2nd Trimester N (%) |
3rd Trimester N (%) |
Entire Pregnancy N (%) |
|
| None | 111 (46.3) | 119 (49.6) | 164 (68.3) | 82 (34.2) | 85 (47.2) | 98 (54.4) | 126 (70.0) | 64 (35.6) |
| Any | 129 (53.8) | 121 (50.4) | 76 (31.7) | 158 (65.8) | 95 (52.8) | 82 (45.6) | 54 (30.0) | 116 (64.4) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Mean (SD) | 14.3 (29.1) | 23.1 (49.3) | 14.5 (24.9) | 36.3 (73.5) | 16.4 (32.2) | 24.9 (47.2) | 14.3 (23.6) | 37.7 (71.4) |
| Median (IQR) | 4.5 (11.0) | 9.0 (14.0) | 4.0 (11.6) | 13.8 (31.5) | 5.8 (16.5) | 9.0 (16.0) | 5.3 (10.0) | 13.0 (34.5) |
| Range | 1.0 - 248.5 | 0.5 - 339.0 | 0.5 - 119.5 | 1.0 - 550.5 | 1.0 - 248.5 | 0.5 - 302.0 | 0.5 - 119.5 | 1.0 - 550.5 |
| Formulation | ||||||||
| Paracetamol alone | 105 (81.4) | 97 (80.2) | 63 (82.9) | 120 (75.9) | 77 (81.1) | 62 (75.6) | 43 (79.6) | 87 (75.0) |
| Paracetamol in combination | 14 (10.9) | 12 (9.9) | 7 (9.2) | 15 (9.5) | 12 (12.6) | 11 (13.4) | 6 (11.1) | 14 (12.1) |
| with other active ingredients | ||||||||
| Multiple formulations | 10 (7.8) | 12 (9.9) | 6 (7.9) | 23 (14.6) | 6 (6.3) | 9 (11.0) | 5 (9.3) | 15 (12.9) |
| Indication | ||||||||
| Pain | 96 (74.4) | 90 (74.4) | 57 (75.0) | 100 (63.3) | 67 (70.5) | 58 (70.7) | 38 (70.4) | 71 (61.2) |
| Other | 21 (16.3) | 16 (13.2) | 11 (14.5) | 28 (17.7) | 18 (18.9) | 13 (15.9) | 11 (20.4) | 22 (19.0) |
| Multiple reasons given | 12 (9.3) | 12 (9.9) | 6 (7.9) | 29 (18.4) | 10 (10.5) | 9 (11.0) | 4 (7.4) | 22 (19.0) |
| Missing | 0 (0.0) | 3 (2.5) | 2 (2.6) | 1 (0.6) | 0 (0.0) | 2 (2.4) | 1 (1.9) | 1 (0.9) |